PALI · Palisade Bio, Inc.

Palisade Bio’s Q1 2026 financial results reflect a deliberate acceleration of its lead program PALI-2108, with R&D expenses increasing $5.4 million year-over-year—driven by clinical trial execution, expanded personnel costs (including non-cash share-based compensation), and CMC investments necessary for Phase 2 readiness. The $9.6 million net loss aligns with the company’s clinical-stage profile and reflects no revenue generation, consistent with prior periods. Management highlighted that the Phase 1b fibrostenotic Crohn’s disease cohort reinforced PALI-2108’s pharmacological differentiation: sustained active metabolite exposure above IC90 thresholds in colon tissue, favorable distribution to disease sites, and modulation of both inflammatory and fibrotic pathways—supporting advancement into two parallel Phase 2 trials. The company confirmed IND submissions for ulcerative colitis (targeted for 2Q 2026) and Crohn’s disease (2H 2026), with trial initiations slated for Q3 2026 and Q1 2027, respectively. Critically, the $132.6 million cash position provides runway through major value inflection points—the Phase 2 UC primary efficacy readout expected in 2H 2027 and the Phase 2 CD readout in early 2028—reducing near-term financing risk. While EPS widened versus prior-year, the magnitude is fully attributable to planned investment; the absence of guidance or revised cash runway expectations signals confidence in current execution and timeline adherence. No material changes to capital structure, governance, or strategic direction were disclosed.